https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001
Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
0
fool:-6439001316408559179
0
https://www.zacks.com/stock/news/2238077/novo-nordisk-nvo-up-on-upbeat-data-from-new-obesity-pill-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238077
Mar 08, 2024 - Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
zc:-6632016347588930676
0
https://www.zacks.com/commentary/2232860/top-research-reports-for-nvidia-visa-amgen?cid=CS-ZC-FT-research_daily-2232860
Feb 28, 2024 - Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Visa Inc. (V) and Amgen Inc. (AMGN).
zc:3063361431494597975
0
https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390
Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
zc:6928781431631922699
0
https://www.zacks.com/stock/news/2224255/pbyi-vs-amgn-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2224255
Feb 09, 2024 - PBYI vs. AMGN: Which Stock Is the Better Value Option?
zc:5565331163587547925
0
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
zc:3389672683287065650
0
https://seekingalpha.com/article/4668054-amgen-inc-amgn-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Feb 06, 2024 - Amgen Inc. (NASDAQ:NASDAQ:AMGN) Q4 2023 Earnings Conference Call February 6, 2024 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway -...
0
sa:995548650673872509
0
https://www.zacks.com/stock/news/2222222/amgen-amgn-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2222222
Feb 06, 2024 - Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zc:4286218058923153710
0
https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221113
Feb 05, 2024 - Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
zc:-8889128175318834178
0
https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-2220511
Feb 02, 2024 - AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
zc:-2017038614076952031
0